Abstract
Anticoagulation reversal in patients with left ventricular assist devices (LVAD) after acute hemorrhagic stroke must occur rapidly to prevent hemorrhage expansion and limit neurologic sequelae, keeping in mind the risk of thrombotic complications. The purpose of this study was to report a case series of our initial experience using a recently FDA approved (April 2013) 4-factor prothrombin complex concentrate (4F-PCC) for INR normalization after acute hemorrhagic stroke in LVAD patients, and compare the results with traditional INR reversal agents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.